[The impact of the COVID-19 pandemic on first-line primary care in southeastern France: Feedback on the implementation of a real-time monitoring system based on regional health insurance data].
L’impact de l’épidémie de COVID-19 sur les soins de premier recours en région Provence-Alpes-Côte d’Azur : retour d’expérience sur la mise en place d’un dispositif de surveillance en temps réel à partir des données régionales de l’Assurance maladie.
COVID-19
Drugs
Healthcare use
Medical practitioners
Médecins
Médicaments
Outpatient care
Public health
Recours aux soins
Santé publique
Soins de ville
Vaccination
Journal
Revue d'epidemiologie et de sante publique
ISSN: 0398-7620
Titre abrégé: Rev Epidemiol Sante Publique
Pays: France
ID NLM: 7608039
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
23
11
2020
revised:
02
04
2021
accepted:
12
04
2021
pubmed:
17
5
2021
medline:
22
6
2021
entrez:
16
5
2021
Statut:
ppublish
Résumé
Starting in spring 2020, the COVID-19 pandemic markedly impacted the French healthcare system. Lockdown and risks of exposure to the coronavirus induced patients to modify their ways of use. The objective of this article was to share feedback on the implementation of a real-time monitoring system concerning (a) the activity of private practitioners in southeastern France, and (b) the evolution of reimbursements for drugs prescribed to persons with diabetes, for treatment of mental health disorders, and for performance of some vaccines. Data regarding 2019 and 2020 were extracted from regional health insurance databases. They were used to elaborate several indicators relative to the general health insurance scheme, which were calculated and updated each week, starting with week 2. We observed a drop in private physician activity during the lockdown (-23% for general practitioners; -46% for specialist doctors), followed by a return to a semblance of normalcy. Concomitantly, a boom in teleconsultations occurred: at the height of the crisis they represented 30% of medical acts. The initial stage of the lockdown was characterized by peak provisioning for drugs, whereas vaccination strongly declined (-39% regarding measles, mumps and rubella vaccine among children aged less than 5 years; -54% regarding human papillomavirus vaccine among girls aged 10 to 14 years). The COVID-19 pandemic could lead to health effects other than those directly attributable to the coronavirus itself. Renouncing care may result in healthcare delays highly deleterious for people and society. Public authorities are preoccupied with these questions; they have set up action plans aimed at encouraging patients to seek treatment without delay. That said, the COVID-19 pandemic crisis has also created opportunities, such as the expansion of telemedicine. Although partial, these indicators can provide useful information enabling public decision makers to be reactive and to implement specific actions to meet the health needs of the population.
Sections du résumé
BACKGROUND
BACKGROUND
Starting in spring 2020, the COVID-19 pandemic markedly impacted the French healthcare system. Lockdown and risks of exposure to the coronavirus induced patients to modify their ways of use. The objective of this article was to share feedback on the implementation of a real-time monitoring system concerning (a) the activity of private practitioners in southeastern France, and (b) the evolution of reimbursements for drugs prescribed to persons with diabetes, for treatment of mental health disorders, and for performance of some vaccines.
METHODS
METHODS
Data regarding 2019 and 2020 were extracted from regional health insurance databases. They were used to elaborate several indicators relative to the general health insurance scheme, which were calculated and updated each week, starting with week 2.
RESULTS
RESULTS
We observed a drop in private physician activity during the lockdown (-23% for general practitioners; -46% for specialist doctors), followed by a return to a semblance of normalcy. Concomitantly, a boom in teleconsultations occurred: at the height of the crisis they represented 30% of medical acts. The initial stage of the lockdown was characterized by peak provisioning for drugs, whereas vaccination strongly declined (-39% regarding measles, mumps and rubella vaccine among children aged less than 5 years; -54% regarding human papillomavirus vaccine among girls aged 10 to 14 years).
CONCLUSION
CONCLUSIONS
The COVID-19 pandemic could lead to health effects other than those directly attributable to the coronavirus itself. Renouncing care may result in healthcare delays highly deleterious for people and society. Public authorities are preoccupied with these questions; they have set up action plans aimed at encouraging patients to seek treatment without delay. That said, the COVID-19 pandemic crisis has also created opportunities, such as the expansion of telemedicine. Although partial, these indicators can provide useful information enabling public decision makers to be reactive and to implement specific actions to meet the health needs of the population.
Identifiants
pubmed: 33992499
pii: S0398-7620(21)00212-1
doi: 10.1016/j.respe.2021.04.135
pmc: PMC8075812
pii:
doi:
Types de publication
Journal Article
Langues
fre
Sous-ensembles de citation
IM
Pagination
105-115Informations de copyright
Copyright © 2021 Elsevier Masson SAS. All rights reserved.
Références
Eur J Gen Pract. 2020 Dec;26(1):129-133
pubmed: 32985278
Ethics Med Public Health. 2020 Oct-Dec;15:100571
pubmed: 32838000
Encephale. 2020 Jun;46(3S):S81-S84
pubmed: 32471705
J Am Board Fam Med. 2021 Feb;34(Suppl):S61-S70
pubmed: 33622820
Euro Surveill. 2018 Nov;23(48):
pubmed: 30514414
Nat Med. 2020 May;26(5):665-671
pubmed: 32405058
J Am Med Inform Assoc. 2020 Jul 1;27(7):1132-1135
pubmed: 32324855
Gen Psychiatr. 2020 Sep 22;33(5):e100299
pubmed: 33083692
J Interprof Care. 2020 Sep-Oct;34(5):672-678
pubmed: 32962462
Int J Public Health. 2020 Dec;65(9):1525-1527
pubmed: 32857238
Encephale. 2020 Jun;46(3S):S3-S13
pubmed: 32312567
JAMA Netw Open. 2020 Oct 1;3(10):e2021476
pubmed: 33006622
Rev Med Interne. 2020 Jun;41(6):358-359
pubmed: 32540118
Encephale. 2020 Jun;46(3S):S43-S52
pubmed: 32370983
J Cancer Surviv. 2017 Feb;11(1):92-101
pubmed: 27553640
J Sleep Res. 2021 Feb;30(1):e13119
pubmed: 32596936
Sci Rep. 2020 Sep 23;10(1):15514
pubmed: 32968181
Intern Emerg Med. 2020 Aug;15(5):787-790
pubmed: 32519136
J Gen Intern Med. 2019 Oct;34(10):2260-2263
pubmed: 31243711
BJGP Open. 2020 Oct 27;4(4):
pubmed: 32900708
N Engl J Med. 2020 Apr 30;382(18):1679-1681
pubmed: 32160451
Ann Med Psychol (Paris). 2020 Sep;178(7):669-671
pubmed: 32958961
Bull Cancer. 2020 Jun;107(6):620-622
pubmed: 32389352
Lancet Public Health. 2020 Aug;5(8):e437-e443
pubmed: 32473113
Therapie. 2001 Jan-Feb;56(1):11-4
pubmed: 11322011